Head-To-Head Analysis: Pivotal Therapeutics (OTCMKTS:PVTTF) versus Cardiol Therapeutics (NASDAQ:CRDL)

Cardiol Therapeutics (NASDAQ:CRDL) and Pivotal Therapeutics (OTCMKTS:PVTTF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Profitability

This table compares Cardiol Therapeutics and Pivotal Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-217.53%	-153.67%
Pivotal Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Cardiol Therapeutics and Pivotal Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1	0	2	2	3.00
Pivotal Therapeutics	0	0	0	0	0.00

Cardiol Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 692.08%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cardiol Therapeutics is more favorable than Pivotal Therapeutics.

Volatility and Risk

Cardiol Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Pivotal Therapeutics has a beta of -1.11, meaning that its stock price is 211% less volatile than the S&P 500.

Earnings and Valuation

This table compares Cardiol Therapeutics and Pivotal Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$26.77 million	($0.30)	-3.37
Pivotal Therapeutics	N/A	N/A	N/A	N/A	N/A

Summary

Cardiol Therapeutics beats Pivotal Therapeutics on 7 of the 9 factors compared between the two stocks.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

About Pivotal Therapeutics

Pivotal Therapeutics Inc., a specialty pharmaceutical company, focuses on the treatment of cardiovascular diseases and overall health. Its lead product, VASCAZEN, is a prescription only medical food formulated for clinical dietary management of cardiovascular disease in patients with documented coronary heart disease and who are deficient in blood Omega-3 fatty acids, eicosapentaenoic acid, and docosahexanenoic acid levels. The company also offers OMAZEN for the maintenance of good health through elevating Omega-3 fatty acid levels. In addition, the company develops Benefishial product line for overall health, cardiovascular health, prenatal health, toddler’s health, child’s health, and pet’s health. Further, it is developing PVT-100 indicated for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. Pivotal Therapeutics Inc. sells VASCAZEN in the United States and OMAZEN in Canada. The company is headquartered in Woodbridge, Canada.